Jazz Pharmaceuticals plc, which recently agreed to acquire Redx’s KRAS (Kirsten rat sarcoma virus) inhibitor program, has appointed Philip Johnson as Executive Vice President and Chief Financial Officer, effective March 1, 2024.   Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023. Experience Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company’s treasury and inv...